Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

Arrowhead stock soars on $825M Sarepta Therapeutics deal

admin by admin
November 26, 2024
in Stock
0
Arrowhead stock soars on $825M Sarepta Therapeutics deal
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

On Tuesday, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shares surged by 32% following the announcement of a comprehensive licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ:SRPT). The transaction, poised to close in early 2025, will see Arrowhead receiving an immediate $825 million, including a $500 million upfront payment and a $325 million equity investment at a 35% premium. Additionally, Arrowhead is set to receive $250 million over the next five years and could earn up to $10 billion in future milestone payments, along with royalties on product sales.

The partnership grants Sarepta access to Arrowhead’s Targeted RNAi Molecule (TRiM) platform to develop treatments for rare genetic diseases affecting muscles, the central nervous system, and lungs. Sarepta will also have the option to select up to six new targets for Arrowhead to explore in preclinical development.

Arrowhead’s President and CEO, Christopher Anzalone, Ph.D., highlighted the deal’s significance, stating it provides “a transformational amount of capital” and the potential for substantial non-dilutive funding. The agreement is expected to extend Arrowhead’s cash runway into 2028, supporting the launch of its investigational drug plozasiran and the advancement of its pipeline programs.

In conjunction with the agreement, Sarepta’s President and CEO, Doug Ingram, will join Arrowhead’s Board of Directors, bringing his extensive experience in advancing investigational medicines and launching commercial drugs.

Arrowhead is on track to receive an additional $300 million in near-term clinical trial enrollment-related payments within the next 12 months. The company is also eligible for development milestone payments ranging from $110 million to $410 million per program and sales milestone payments between $500 million and $700 million per program. Arrowhead will also earn tiered royalties on commercial sales.

The current clinical programs under the agreement include ARO-DUX4 for facioscapulohumeral muscular dystrophy type 1, ARO-DM1 for type 1 myotonic dystrophy, ARO-MMP7 for idiopathic pulmonary fibrosis, and ARO-ATXN2 for spinocerebellar ataxia 2. Preclinical programs ARO-HTT, ARO-ATXN1, and ARO-ATXN3 are expected to be ready for clinical trial applications in the coming years.

Arrowhead will discuss the details of this agreement during its fiscal year-end results conference call on Tuesday, November 26, 2024, at 4:30 p.m. ET. The closing of the transaction is contingent upon regulatory approvals and customary closing conditions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com

Previous Post

What Scott Bessent’s Treasury nomination could mean for the economy, tariffs

Next Post

Best Buy annual forecasts take a knock from weak electronics demand

admin

admin

Next Post
Best Buy annual forecasts take a knock from weak electronics demand

Best Buy annual forecasts take a knock from weak electronics demand

Trending News

HCA Healthcare misses quarterly profit estimates on hurricane impact

HCA Healthcare misses quarterly profit estimates on hurricane impact

October 25, 2024
Italian lender UniCredit proposes $10.5 billion acquisition of rival Banco BPM

Italian lender UniCredit proposes $10.5 billion acquisition of rival Banco BPM

November 25, 2024
Elon Musk downplays SpaceX Starship explosion, calls it ‘just a scratch’

Elon Musk downplays SpaceX Starship explosion, calls it ‘just a scratch’

June 19, 2025
Subscribe to Insightful Word


    Recent News

    Jaguar Land Rover to cut 500 UK jobs as US tariffs dent exports

    Jaguar Land Rover to cut 500 UK jobs as US tariffs dent exports

    July 17, 2025
    Oracle stock price has surged, but beware of key risks

    Oracle stock price has surged, but beware of key risks

    July 17, 2025
    Starbucks shares slip after Jefferies downgraded the stock

    Starbucks shares slip after Jefferies downgraded the stock

    July 17, 2025
    US stocks open in the green: Dow Jones up 150 points, Nasdaq up 0.2%

    US stocks open in the green: Dow Jones up 150 points, Nasdaq up 0.2%

    July 17, 2025

    Recent News

    Jaguar Land Rover to cut 500 UK jobs as US tariffs dent exports

    Jaguar Land Rover to cut 500 UK jobs as US tariffs dent exports

    July 17, 2025
    Oracle stock price has surged, but beware of key risks

    Oracle stock price has surged, but beware of key risks

    July 17, 2025

    Latest News

    • Jaguar Land Rover to cut 500 UK jobs as US tariffs dent exports
    • Oracle stock price has surged, but beware of key risks
    • Starbucks shares slip after Jefferies downgraded the stock

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.